Do Prognostic Differences Exist Among High-Risk RET Mutations? A Comparison of Outcomes Between the RET C634R and Other C634 Mutations in Hereditary Medullary Thyroid Carcinoma
Thyroid® · 01.11.2025 · 35 (11) · 1259-1267
DOI: 10.1177/10507256251372196 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Thyroid®, online erschienen am 11.12.2025. Verfasst von Jie Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong Universit…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Thyroid Neoplasms, Mutation, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: the São Paulo State Research Foundation, the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences, the National Science Foundation of China.
Abstract (Originalsprache)
Background
The American Thyroid Association has stratified RET C634 mutations as high risk. The association between RET C634R mutation and a more aggressive medullary thyroid carcinoma (MTC) behavior compared with other C634 mutations remains inconclusive, possibly due to the lack of large cohorts and long-term outcome data. This study aimed to evaluate the aggressiveness and long-term outcomes of hereditary MTC in patients with different RET codon 634 mutations.
Methods
This study is an international, multicenter, retrospective cohort study. Data from patients with hereditary MTC carrying RET codon 634 mutations treated at three tertiary medical centers were retrospectively analyzed. Clinicopathological features and long-term outcomes were compared between patients with the C634R and those with other C634 mutations (C634F/G/S/W/Y).
Results
The study cohort included 317 patients (C634R: 133; C634F/G/S/W/Y: 184) from 137 families with a median follow-up of 10.6 years (4.9–16.6 years). Patients with the C634R mutation were slightly younger at the time of initial surgery (27.8 ± 12.1 vs. 31.3 ± 14.9, p = 0.025). Meanwhile, the C634R group showed larger primary tumors (1.9 ± 1.2 vs. 1.5 ± 1.1, p = 0.006). Kaplan–Meier analysis revealed significantly higher cumulative rates and earlier occurrence of lymph node metastases ( p = 0.0003) and extrathyroidal extension (ETE; p < 0.0001) in the C634R group. The C634R mutation was significantly associated with distant metastases (hazard ratio [HR]: 2.545 [confidence interval (CI) 1.134–5.713]; p = 0.024). Moreover, multivariable analysis identified RET C634R genotype (HR: 6.488 [CI 1.364–30.862]; p = 0.019), increasing age (HR: 1.082 [CI 1.023–1.144]; p = 0.006), and ETE (HR: 9.695 [CI 2.344–40.105]; p = 0.002) to be significantly associated with worse disease-specific survival.
Conclusions
Prognosis varied in hereditary MTC patients with RET C634 mutations. Our data highlight that the RET C634R mutation was associated with greater tumor aggressiveness in MTC and a poorer disease-specific survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai National Clinical Research Center for M…
- Division of Endocrinology, São Paulo Cancer Institute (ICESP), São Paulo, Brazil.
- Laboratory of Molecular and Translational Endocrinology, Division of Endocrinology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil.
- Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Ultrasound, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Luciana Audi Castroneves, Lei Ye
Förderung
- the São Paulo State Research Foundation
- the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
- the National Science Foundation of China
Zitieren
APA
Zhang, J., Castroneves, L. A., Lindsey, S. C., Han, R., Liu, Z., Li, Y., Xie, J., Zhou, W., Song, Q., Camacho, C. P., Zhao, Y., Xie, X., Zhou, Y., Yan, J., Ning, G., Wang, W., Maciel, R. M. B., Hoff, A. O., & Ye, L. (2025). Do Prognostic Differences Exist Among High-Risk RET Mutations? A Comparison of Outcomes Between the RET C634R and Other C634 Mutations in Hereditary Medullary Thyroid Carcinoma. Thyroid®, 35(11), 1259-1267. https://doi.org/10.1177/10507256251372196
Vancouver
Zhang J, Castroneves LA, Lindsey SC, Han R, Liu Z, Li Y, et al. Do Prognostic Differences Exist Among High-Risk RET Mutations? A Comparison of Outcomes Between the RET C634R and Other C634 Mutations in Hereditary Medullary Thyroid Carcinoma. Thyroid®. 2025;35(11):1259-1267. doi:10.1177/10507256251372196
BibTeX
@article{Zhang2025,
author = {Zhang, Jie and Castroneves, Luciana Audi and Lindsey, Susan C and Han, Rulai and Liu, Ziyuan and Li, Yue and Xie, Jing and Zhou, Wei and Song, Qi and Camacho, Cleber P and Zhao, Yu and Xie, Xiaoyan and Zhou, Yulin and Yan, Jiqi and Ning, Guang and Wang, Weiqing and Maciel, Rui M B and Hoff, Ana O and Ye, Lei},
title = {Do Prognostic Differences Exist Among High-Risk RET Mutations? A Comparison of Outcomes Between the RET C634R and Other C634 Mutations in Hereditary Medullary Thyroid Carcinoma},
journal = {Thyroid®},
year = {2025},
volume = {35},
number = {11},
pages = {1259--1267},
doi = {10.1177/10507256251372196}
}
EUVIMED